Amgen Inc ((AMGN)), AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc and AstraZeneca have announced a new clinical study titled A Multicentre, Randomised, Double-Blind, Parallel-Group Placebo-Controlled, Phase 3, Efficacy and Safety Study of Tezepelumab in 5 to < 12 Year Old Children With Severe Uncontrolled Asthma (HORIZON). This study aims to evaluate the efficacy and safety of tezepelumab, a potential treatment for pediatric patients with severe uncontrolled asthma, highlighting its significance in addressing unmet medical needs in this demographic.
The study tests the biological intervention, tezepelumab, administered via subcutaneous injections. It is compared against a placebo to determine its effectiveness in managing severe asthma in children.
The study follows a randomized, parallel-group design with triple masking, ensuring that participants, care providers, and investigators are unaware of the treatment allocations. The primary purpose is treatment-focused, aiming to provide insights into the therapeutic potential of tezepelumab.
The study began on August 24, 2023, with an anticipated primary completion date in 2025. The last update was submitted on August 5, 2025, indicating ongoing progress and commitment to this research.
This clinical update could positively influence the stock performance of Amgen and AstraZeneca by potentially expanding their portfolio in pediatric asthma treatments. As the study progresses, investor sentiment may shift favorably, especially if interim results show promising outcomes, setting a competitive edge in the respiratory treatment market.
The study is currently recruiting, with further details available on the ClinicalTrials portal.